All In Biotech

NDA 214273 · Azurity

Zonisade

Zonisamide · Oral · Anti-epileptic Agent

Last checked: Nov 20, 2026Latest source record: Jul 15, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Jul 15, 2022

Approved uses

1

Original approval plus efficacy supplements

Registered trials

79

22 Phase 3, 1 recruiting

FAERS reports

10,721

8,243 serious, 683 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 8, 2025.

ZONISADE is indicated as adjunctive therapy for the treatment of partial-onset seizures in adults and pediatric patients 16 years and older. ZONISADE is indicated as adjunctive therapy for the treatment of partial-onset seizures in adults and pediatric patients 16 years of age and older ( 1 ).

Mechanism: The precise mechanism(s) by which zonisamide exerts its anticonvulsant effects is unknown. Zonisamide may produce these effects through action at sodium and calcium channels. In vitro pharmacological studies suggest that zonisamide blocks sodium channels and reduces voltage-dependent, transient inward currents (T-type Ca2+ currents), consequently stabilizing neuronal membranes. Other in vitro studies have demonstrated that zonisamide (10–30 µg/mL) suppresses synaptically-driven electrical activity without affecting postsynaptic GABA or glutamate responses (cultured mouse spinal cord neurons)...

Therapeutic areas: Neurology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ZONISADE · ZONISAMIDE 100MG/5ML · SUSPENSION, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Zonisamide" as an intervention, any sponsor and status, largest first.

All 79 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,397
  • seizure1,228
  • off label use819
  • fatigue501
  • somnolence478
  • dizziness402
  • nausea387
  • fall370
  • headache364
  • condition aggravated362
  • drug interaction336
  • vomiting321

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200429
200552
200699
2007115
2008139
2009151
2010165
2011292
2012320
2013240
2014292
2015400
2016544
2017493
2018674
2019816
2020726
2021970
2022968
2023917
2024881
2025856
2026582

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zonisade (Zonisamide)

2024 spending

$4.4M

Beneficiaries

515

3,923 claims

Per beneficiary

$8,571

$2.57 per unit

View as table
YearSpending
2020$0
2021$0
2022$113,264
2023$2,053,224
2024$4,413,917

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 224 on PubMed

Sponsor: Azurity

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.